Migraine
NEJM 377:553-561, Charles, A., 2017
Migraine
NEJM 383:1866-1876, Ashina, M., 2020
Abdominal Migraine
BMJ 360;k179, Angus-Leppan, H.,et al, 2018
CGRP - The Next Frontier for Migraine
NEJM 377:2190-2191, Hershey, A.D., 2017
Chronic Migraine
BMJ 348:g141b, Schwedt, T.J., 2014
Triptan Therapy in Migraine
NEJM 363:63-70, Loder,E., 2010
Migraine and Other Headaches
Neurol 63:2233-2239,2209, Rose,K.M.,et al, 2004
The Safety of Triptans in the Treatment of Patients with Migraine
Am J Med 112:135-140, Jamieson,D.G., 2002
Analgesic Headache
BMJ 310:479-480, Olesen,J., 1995
Atogepant for the Preventive Treatment of Chronic Migraine (PROGRESS): A Randomised, Double-blind, Placebo-controlled, Phase 3 Trial
Lancet 402:775-785, Pozo-Rosich,P.,et al, 2023
Acute Treatment for Migraine
JAMA 325:2346-2347, Burch, R. & Rayhill, M., 2021
Acute Treatment of Migraine in Children and Adolescents
Neurol 93:487-499, Oskoui, M.,et al, 2019
Fremanezumab versus Placebo for Migraine Prevention in Patients with Documented Failure to Up to Four Migraine Preventive Medication Classes (FOCUS): A Randomised, Double-Blind, Placebo-Controlled, Phase 3� Trial
Lancet 394:1030-1040, Ferrari, M.D.,et al, 2019
Targeting Calcitonin Gene-Related Peptide: A New Era in Migraine Therapy
Lancet 394:1765-1774, Charles, A. & Pozo-Rosich, P., 2019
Efficacy and Tolerability of Erenumab in Patients with Episodic Migraine in Whom Two-of-Four Previous Preventive Treatments were Unsuccessful: A Randomised, Double-Blind, Placebo-Controlled, Phase 3b Study
Lancet 392:2280-2287,2241, Reuter, U.,et al, 2018
Galcanezumab in Chronic Migraine
Neurol 91:e2211-e2221, Detke, H.C.,et al, 2018
Evidence-Based Treatments for Adults with Migraine
Pain Reser Treat 2015:DOI:10.1155/2015/629382, Gooriah, R.,et al, 2015
Comorbidity of Migraine in Children Presenting with Epilepsy to a Tertiary Care Center
Neurol 79:468-473, Kelly, S.A.,et al, 2012
Tricyclic Antidepressants and Headaches: Systematic Review and Meta-Analysis
BMJ 341:c5222, Jackson,J.L.,et al, 2010
Oxcarbazepine in Migraine Headache: A Double-Blind, Randomized, Placebo-Controlled Study
Neurol 70:548-555, Silberstein,S.,et al, 2008
Headache and Pregnancy
The Neurologist 14:108-119, Menon,R. &Bushnell,C.D., 2008
Sumatriptan-Naproxen for Acute Treatment of Migraine, A Randomized Trial
JAMA 297:1443-1454, Brandes,J.L.,et al, 2007
Migraine--Current Understanding and Treatment
NEJM 346:257-270, Goadsby,P.J.,et al, 2002
What Matters is Not the Differences Between Triptans, but the Differences Between Patients
Arch Neurol 58:1481-1482, Saper,J.R., 2001
Triptans Are All Different
Arch Neurol 58:1479-1480,1482, Rapoport,A.M.&Tepper,S.J., 2001
Rizatriptan (MAXALT) for the Acute Treatment of Migraine & Migraine Recurrence, Rizatriptan 022 Study Grp
Headache 38:281-287, Tuchman,T.J.,et al, 1998
Butorphanol (Stadol) :A Study in Problems of Current Drug Information and Control
Neurol 48:1156-1160, Fisher,M.A.&Glass,S., 1997
Optimizing the Dose of Zolmitriptan (Zomig, *311C90) for the Acute Treatment of Migraine
Neurol 49:1210-1218, 11931997., Rapoport,A.M.,et al, 1997
Sumatriptan in Clinical Practice:A 2-year Review of 453 Migraine Patients
Neurol 47:46-51, Visser,W.H.,et al, 1996
Rizatriptan vs Sumatriptan in Acute Trmt of Migraine. Dutch/US Rizatriptan Study Group
Arch Neurol 53:1132-1137, Visser,W.H.,et al, 1996
Headache
JNNP 57:134-143, Pearce,J.M.S., 1994
Clinical Exper from Sweden on Use of Subcutaneously Admin Sumatriptan in Migraine & Cluster Headache
Arch Neurol 51:1256-1261, Dahlof,C.,et al, 1994
Sumatriptan
Lancet 341:221-224, Bateman,D.N., 1993
Efficacy of Subcutaneous Sumatriptan in Repeated Episodes of Migraine
Neurol 43:1363-1368, Cady,R.K.,et al, 1993
Sumatriptan for Migraine
The Medical Letter, 34:91-931992., , 1992
Abrupt Outpatient Withdrawal of Medication in Analgesic-Abusing Migraineurs
Lancet 337:1442-1443, Hering,T.&Steiner,T.J., 1991
Treatment of Acute Migraine with Subcutaneous Sumatriptan
JAMA 265:2831-2835, Cady,R.K.,et al, 1991
Treatment of Migraine Attacks with Sumatriptan
The Subcutaneous Sumatriptan International Study Group, NEJM 325:316-321, 353-354991., , 1991
Possible Benefit of GR43175, A Novel 5-HT1-Like Receptor Agonist for the Acute Treatment of Severe Migraine
Lancet 1:1309-1311, Doenicke,A.,et al, 1988
Trauma-Triggered Migraine:An Explanation for Common Neurological Attacks after Mild Head Injury
J Neurosurg 68:181-188, Haas,D.C.&Lourie,H., 1988
One-Year Sustained Efficacy of Erenumab in Episodic Migraine
Neurol 95:e469-e479, Goadsby, P.J.,et al, 2020
Erenumab in Chronic Migraine
Neurol 92:e2250-e2260, Lipton, R.B.,et al, 2019
Remigepant, an Oral Calcitonin Gene-Related Peptide Receptor Antagonist, for Migraine
NEJM 381:142-149, Lipton, R.B.,et al, 2019
Ubrogepant for the Treatment of Migraine
NEJM 381:2230-2241, Dodick, D.W.,et al, 2019
Noninvasive Vagus Nerve Stimulation as Acute Therapy for Migraine
Neurol 91:e364-e373, Tassorelli,C., et al, 2018
Preventive Migraine Drug Approved
JAMA 320:1746, , 2018
Lasmiditan is an Effective Acute Treatment for Migraine
Neurol 91:e2222-e2232, Kuca, B.,et al, 2018
Practice Guideline Update Summary: Botulinum Neurotoxin for the Treatment of Blepharospasm, Cervical Dystonia, Adult Spasticity, and Headache
Neurol 86:1818-1826, Simpson, D.M.,et al, 2016
Triptans for Symptomatic Treatment of Migraine Headache
BMJ 348:g2285, Pringsheim, T. & Becker, W.J., 2014